Patient characteristics
. | Total . | ABVD + RT . | ABVD . |
|---|---|---|---|
| Total patients | 152 | 76 | 76 |
| No. ineligible | 0 | 0 | 0 |
| Median age, y (range) | 31.5 (15-68) | 29 (15-66) | 33 (16-68) |
| Sex, no. (%) | |||
| Male | 87 (57) | 38 | 49 |
| Female | 65 (43) | 38 | 27 |
| Histology, no. (%) | |||
| NS | 115 (76) | 59 | 56 |
| MC | 21 (14) | 7 | 14 |
| LP | 14 (9) | 8 | 6 |
| Not subclassified | 2 (1) | 2 | 0 |
| Stage, no. (%) | |||
| IA | 28 (18) | 9 | 19 |
| IIA | 88 (58) | 51 | 37 |
| IIB | 16 (11) | 7 | 9 |
| IIIA | 20 (13) | 9 | 11 |
| ESR, no (%) | 134 | 66 | 68 |
| A more than 50 mm/h | 19 (14) | 10 | 9 |
| B more than 30 mm/h | 7 (5) | 4 | 3 |
| No. of sites involved, no. (%) | 152 | 76 | 76 |
| 1 to 2 | 61 (40) | 35 | 26 |
| 3 | 33 (22) | 14 | 19 |
| More than 3 | 58 (38) | 27 | 31 |
. | Total . | ABVD + RT . | ABVD . |
|---|---|---|---|
| Total patients | 152 | 76 | 76 |
| No. ineligible | 0 | 0 | 0 |
| Median age, y (range) | 31.5 (15-68) | 29 (15-66) | 33 (16-68) |
| Sex, no. (%) | |||
| Male | 87 (57) | 38 | 49 |
| Female | 65 (43) | 38 | 27 |
| Histology, no. (%) | |||
| NS | 115 (76) | 59 | 56 |
| MC | 21 (14) | 7 | 14 |
| LP | 14 (9) | 8 | 6 |
| Not subclassified | 2 (1) | 2 | 0 |
| Stage, no. (%) | |||
| IA | 28 (18) | 9 | 19 |
| IIA | 88 (58) | 51 | 37 |
| IIB | 16 (11) | 7 | 9 |
| IIIA | 20 (13) | 9 | 11 |
| ESR, no (%) | 134 | 66 | 68 |
| A more than 50 mm/h | 19 (14) | 10 | 9 |
| B more than 30 mm/h | 7 (5) | 4 | 3 |
| No. of sites involved, no. (%) | 152 | 76 | 76 |
| 1 to 2 | 61 (40) | 35 | 26 |
| 3 | 33 (22) | 14 | 19 |
| More than 3 | 58 (38) | 27 | 31 |
NS indicates nodular sclerosis; MC, mixed cellularity; LP, lymphocyte predominance; ESR, erythrocyte sedimentation rate.